$3.30
2.84% today
Nasdaq, Apr 03, 06:19 pm CET
ISIN
US63009J1079
Symbol
NBTX
Sector
Industry

Nanobiotix - ADR Stock price

$3.40
-0.14 3.99% 1M
-1.79 34.49% 6M
+0.53 18.47% YTD
-2.70 44.26% 1Y
-4.04 54.30% 3Y
-10.10 74.81% 5Y
-10.10 74.81% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.18 5.03%
ISIN
US63009J1079
Symbol
NBTX
Sector
Industry

Key metrics

Market capitalization $160.18m
Enterprise Value $141.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.62
P/S ratio (TTM) P/S ratio 4.09
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $39.17m
EBIT (operating result TTM) EBIT $-30.67m
Free Cash Flow (TTM) Free Cash Flow $-9.45m
EPS (TTM) EPS $-0.80
P/E forward negative
P/S forward 7.50
EV/Sales forward 6.63
Short interest 0.02%
Show more

Is Nanobiotix - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Nanobiotix - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Nanobiotix - ADR forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Nanobiotix - ADR forecast:

Buy
90%
Hold
10%

Financial data from Nanobiotix - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
39 39
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
21% 21%
56%
- Research and Development Expense 45 45
30% 30%
114%
-29 -29
46% 46%
-74%
- Depreciation and Amortization 1.69 1.69
8% 8%
4%
EBIT (Operating Income) EBIT -31 -31
45% 45%
-78%
Net Profit -36 -36
41% 41%
-92%

In millions USD.

Don't miss a Thing! We will send you all news about Nanobiotix - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nanobiotix - ADR Stock News

Neutral
GlobeNewsWire
about 21 hours ago
Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Disciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milest...
Neutral
GlobeNewsWire
3 days ago
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST
Neutral
GlobeNewsWire
7 days ago
PARIS and CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering disruptive, nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today announced the first data from the completed dose escalation part of a Phase 1 study sponsored by The Universi...
More Nanobiotix - ADR News

Company Profile

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

Head office France
CEO Laurent Lévy
Founded 2003
Website www.nanobiotix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today